Anti-VEGF and Retinal Dystrophies.

Anti-VEGF and Retinal Dystrophies.
Curr Drug Targets. 2020 Apr 27;:
Authors: Parodi MB, Iacono P, Da Pozzo S
Abstract
The therapeutic approach based on anti-vascular endothelial growth factor (anti-VEGF) molecules can be used to treat two important complications of retinal dystrophies: choroidal neovascularization and macular edema. The macular involvement in retinal dystrophies can lead to further visual deterioration in patients in young age and already affected by functional limitations. The chapter reports the effect of anti-VEGF treatment in several subforms of retinal dystrophies, critically discussing advantages and limitations.
PMID: 32342816 [PubMed - as supplied by publisher]

Source: Current Drug Targets - April 26, 2020 Category: Drugs & Pharmacology Authors: Parodi MB, Iacono P, Da Pozzo S Tags: Curr Drug Targets Source Type: research